Daiichi Sankyo, Lilly Explore Pharmacogenomic Marker For Prasugrel
This article was originally published in PharmAsia News
A May 4 Circulation article describing prasugrel's efficacy in patients who carry a genetic marker indicative of non-response to Plavix may be the opening volley in one of the first big marketing battles of the personalized medicine era
You may also be interested in...
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster
Genetics and concomitant PPI use are possible reasons for the anti-platelet drug’s reduced effectiveness in some patients, according to an FDA “Early Communication.”
Three independent research teams say they have document a strong link between a metabolizing gene and the prognosis for stented heart disease patients taking the standard anti-platelet medicine Plavix.